Cell No. : Cell Name
RCB1695 : RMS-YM
update : 2023/01/05
|
| Comment | Embryonal rhabdomyosarcoma cell line derived from human. Transplantable in nude mouse. |
| Comment from the depositor | |
| Terms and conditions | There is no restriction regarding use for basic researches. In relation to commercial use and use for patent filing, first of all please contact the RIKEN BRC. |
| Remarks | |
| Order Form |
Order Form(C-0005.pdf)
MTA(C-0007.pdf)
MTA(C-0007p.pdf)
|
|
Regarding MTA between user institutions and RIKEN BRC, there are two kinds of MTA, not-for-profit academic purpose (C-XXXX) and for-profit research purpose (C-XXXXp) , depending on the sort of user institutions and the purposes of use. Please use an appropriate MTA(to see). In relation to commercial use and use for patent filing, first of all Please contact RIKEN BRC (cellbank.brc@riken.jp).
|
|
|
Basic information
|
Depositor |
Naoe, Tomoki
|
| Originator |
Kubo, Kazuaki
|
| Year of deposit |
2000
|
| Animal |
_human
< Mammals
|
| Genus |
Homo
|
| Species |
sapiens
|
| Race |
Japanese
|
| Gender |
Male
|
| Age at sampling |
2 years
|
| Tissue |
urachus
|
| Disease name |
embryonal rhabdomyosarcoma
|
| Classification |
cancer
|
| Year of origin |
1988
|
|
Lifespan |
infinite
|
| Morphology |
fibroblast-like
|
| Cellosaurus(Expasy) |
CVCL_A792
|
|
| |
deposit info |
lot info |
|
Medium |
Medium List |
|
Culture type |
|
Adherent cells
|
| Culture medium |
|
RPMI1640 + 20mM HEPES + 10% FBS (heat inactivated) + 0.1mM NEAA
|
| Antibiotics |
|
Free
|
|
Passage method |
|
0.25% Trypsin + 0.02% EDTA
|
Culture information
|
Passage ratio |
|
1 : 8 split
|
| SC frequency |
|
Subculture : 2 times/week
|
| Temperature |
|
37
℃
|
| CO2 concentration |
|
5
%
|
| Freeze medium |
|
Medium + 10% DMSO
|
| Freezing method |
|
Slow freezing
|
| Mycoplasma/Acholeplasma |
|
(-)
|
| Isozyme |
|
LD, NP
|
| Chromosome mode |
|
52-55(50) : 52(2),53(18),54(26),55(4)
|
| STR(human) |
|
OK
|
| Reference information |
Reference |
1
|
| User's Publication |
13
|
| User's Publication |
|
21071
Huang R, Yamamoto T, Nakata E, Ozaki T, Kurozumi K, Wei F, Tomizawa K, Fujimura A.
CDKAL1 Drives the Maintenance of Cancer Stem-Like Cells by Assembling the eIF4F Translation Initiation Complex.
Adv Sci (Weinh)
2023
e2206542
PubMed ID: 36786012
DOI: 10.1002/advs.202206542
|
|
17518
Ishihara Y, Nakamura K, Nakagawa S, Okamoto Y, Yamamoto M, Furukawa T, Kawahara K.
Nucleolar Stress Response via Ribosomal Protein L11 Regulates Topoisomerase Inhibitor Sensitivity of P53-Intact Cancers
Int J Mol Sci
2022
23(24):15986
PubMed ID: 36555627
DOI: 10.3390/ijms232415986
|
|
17667
Hatta M, Kaibori M, Matsushima H, Yoshida T, Okumura T, Hayashi M, Yoshii K, Todo T, Sekimoto M.
Efficacy of a third-generation oncolytic herpes simplex virus in refractory soft tissue sarcoma xenograft models
Mol Ther Oncolytics
2022
25:225-235
PubMed ID: 35615265
DOI: 10.1016/j.omto.2022.04.010
|
|
20470
Sun J, Lin W, Li C, Ueki H, Xue R, Sadahira T, Hu H, Wada K, Li N, Liu C, Araki M, Xu A, Huang P.
Repurposing of posaconazole as a hedgehog/SMO signaling inhibitor for embryonal rhabdomyosarcoma therapy.
Am J Cancer Res
2021
11(9):4528-4540
PubMed ID: 34659903
|
|
13046
Ouchi K, Miyachi M, Yagyu S, Kikuchi K, Kuwahara Y, Tsuchiya K, Iehara T, Hosoi H.
Oncogenic role of HMGA2 in fusion-negative rhabdomyosarcoma cells.
Cancer Cell Int
2020
PubMed ID: 32489328
DOI: 10.1186/s12935-020-01282-z
|
|
13338
Sugito N, Heishima K, Ito Y, Akao Y.
Synthetic MIR143-3p Suppresses Cell Growth in Rhabdomyosarcoma Cells by Interrupting RAS Pathways Including PAX3-FOXO1.
Cancers (Basel)
2020
PubMed ID: 33182548
DOI: 10.3390/cancers12113312
|
|
16817
Kasahara Y, Shin C, Kubo N, Mihara K, Iwabuchi H, Takachi T, Imamura M, Saitoh A, Imai C.
Development and characterisation of NKp44-based chimeric antigen receptors that confer T cells with NK cell-like specificity
Clin Transl Immunology
2020
9(7):e1147
PubMed ID: 32670576
DOI: 10.1002/cti2.1147
|
|
7155
Kuda M, Kohashi K, Yamada Y, Maekawa A, Kinoshita Y, Nakatsura T, Iwamoto Y, Taguchi T, Oda Y.
FOXM1 expression in rhabdomyosarcoma: a novel prognostic factor and therapeutic target.
Tumour Biol.
2016
37:5213-23
PubMed ID: 26553361
DOI: 10.1007/s13277-015-4351-9
|
|
9540
Zenitani M, Nojiri T, Uehara S, Miura K, Hosoda H, Kimura T, Nakahata K, Miyazato M, Okuyama H, Kangawa K.
C-type natriuretic peptide in combination with sildenafil attenuates proliferation of rhabdomyosarcoma cells.
Cancer Med
2016
5:795-805
PubMed ID: 26816265
DOI: 10.1002/cam4.642
|
|
18291
Kakazu N, Yamane H, Miyachi M, Shiwaku K, Hosoi H.
Identification of the 12q15 amplicon within the homogeneously staining regions in the embryonal rhabdomyosarcoma cell line RMS-YM
Cytogenet Genome Res
2014
142(3):167-73
PubMed ID: 24480864
DOI: 10.1159/000357930
|
|
13763
Nagao H, Setoguchi T, Kitamoto S, Ishidou Y, Nagano S, Yokouchi M, Abematsu M, Kawabata N, Maeda S, Yonezawa S, Komiya S.
RBPJ is a novel target for rhabdomyosarcoma therapy
PLoS One
2012
7(7):e39268.
PubMed ID: 22792167
DOI: 10.1371/journal.pone.0039268
|
|
18251
Rouleau C, Smale R, Fu YS, Hui G, Wang F, Hutto E, Fogle R, Jones CM, Krumbholz R, Roth S, Curiel M, Ren Y, Bagley RG, Wallar G, Miller G, Schmid S, Horten B, Teicher BA.
Endosialin is expressed in high grade and advanced sarcomas: evidence from clinical specimens and preclinical modeling
Int J Oncol
2011
39(1):73-89
PubMed ID: 21537839
DOI: 10.3892/ijo.2011.1020
|
|
18724
Kawabata N, Ijiri K, Ishidou Y, Yamamoto T, Nagao H, Nagano S, Maeda S, Komiya S, Setoguch
Pharmacological inhibition of the Hedgehog pathway prevents human rhabdomyosarcoma cell growth
Int J Oncol
2011
39(4):899-906
PubMed ID: 21674124
DOI: 10.3892/ijo.2011.1076
|
Back
Top
CELL BANK Website